NEW YORK (GenomeWeb) – Investment bank First Analysis has initiated coverage of NeoGenomics with an Overweight rating and a price target of $11, citing in part the company's more robust scale and product portfolio after its acquisition of Clarient.

With the integration of Clarient "well underway, NeoGenomics is positioned to take cancer diagnostics market share as a result of its increased scale and now broader and more comprehensive suite of offerings," First Analysis analyst Joseph Munda wrote in a research note Monday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.